Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...
ca.investing.com on MSN15h
Moderna has limited upside: BarclaysBarclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...
Hosted on MSN12h
Why Moderna (MRNA) Stock Is Up TodayWhat Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 11.8% in the morning session after it continued to build on the 3% gain from Friday when it reported fourth-quarter 2024 ...
EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...
BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.
Some tenants in Silver Spring have been without gas for weeks now. Robert F. Kennedy Jr.’s revealed some dark priorities in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback